Close

Baird Maintains Buy on Sarepta Therapeutic (SRPT)

October 3, 2013 8:59 AM EDT Send to a Friend
Baird maintained an Outperform rating on Sarepta Therapeutic (NASDAQ: SRPT) with a price target of $63.00. Analyst Brian Skorney thinks ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login